丨 2025年7月25日星期五丨 NO.4 中慧元通更新招股书，核心产品已商业化 NO.1 维立志博-B暗盘最高涨幅达134% 7月24日， 维立志博-B开启暗盘，最高涨幅达到134.28%。维立志博成立于2012年，是一家处于临床阶 段的生物科技公司，专注于肿瘤、自身免疫性疾病等重大疾病的抗体新药研发。目前，公司拥有1款核 心产品以及13款其他候选药物，其中6款已成功进入临床阶段。 点评：维立志博暗盘大涨，反映市场对其肿瘤及自免领域抗体药研发管线的认可，后续需关注临床进 展，长期价值取决于新药商业化能力。 NO.2 恒瑞医药HRS-1893片获药物临床试验批准通知书 7月24日，恒瑞医药子公司山东盛迪医药收到国家药品监督管理局核准签发关于HRS-1893片的《药物临 床试验批准通知书》，将于近期开展临床试验。HRS-1893片是一种高选择性的心肌肌球蛋白 （Myosin）小分子抑制剂，拟用于治疗射血分数保留的心力衰竭。针对此适应证，国内外尚未有同类 药物获批上市。截至目前，HRS-1893片相关项目累计研发投入约6067万元。 点评：HRS-1893片作为高选择性心肌球蛋白抑制剂，瞄准射血分数保留的心力衰竭 ...

Financial Performance - The group's revenue for the fiscal year ending December 31, 2024, was approximately HKD 1,669,800,000, a decrease of 3.9% compared to the previous year[9]. - Despite the revenue decline, the group achieved a net profit of approximately HKD 307,200,000, an increase of 11.6% year-on-year[9]. - Cash and cash equivalents as of December 31, 2024, were approximately HKD 557,200,000, an increase from HKD 509,800,000 in 2023[12]. - Total assets rose to HKD 2,983.0 million, a 5.5% increase from HKD 2,827.6 million in 2023[65]. - The gross profit margin for 2024 was 89.8%, slightly down from 89.9% in 2023[66]. - The net profit margin improved to 18.4% in 2024, compared to 15.8% in 2023[66]. - Administrative expenses for the year were approximately HKD 217 million, an increase from HKD 213.9 million in the previous year[76]. - Total R&D expenses for the year amounted to approximately HKD 156.6 million, accounting for 9.4% of revenue, compared to 9.5% in the previous year[76]. - The company reported a mid-term dividend of HKD 0.06 per share, paid on September 24, 2024, and proposed a final dividend of HKD 0.06 per share for the fiscal year ending December 31, 2024, subject to shareholder approval[111]. Revenue Breakdown - The ophthalmology and surgical divisions contributed approximately 46.2% and 52.7% to the total revenue, respectively[11]. - The flagship biopharmaceutical products, Beifu Shou® and Beifu Ji® series, accounted for approximately 84.5% of the total revenue, with Beifu Shou® and Beifu Ji® contributing 35.1% and 49.4% respectively[11]. - The ophthalmology segment contributed approximately HKD 771.5 million to revenue, a 2.2% increase from HKD 755.1 million in 2023[73]. - The surgical segment recorded revenue of approximately HKD 879.9 million, a decrease of 9.3% from HKD 970.4 million in 2023[73]. - The bFGF series products accounted for approximately 84.5% of the group's total revenue during the review year[36]. Research and Development - The group has initiated a five-year development plan to enhance its R&D capabilities and solidify its position in the ophthalmology field[22]. - As of the report date, there are 16 R&D projects in various stages, with 4 ophthalmology projects currently in clinical stages, viewed as mid-term growth drivers[22]. - The group holds a total of 100 patents, including 70 invention patents, 15 utility model patents, and 15 design patents[23]. - The company has established multiple R&D bases in Zhuhai, Boston, London, and Singapore to support the development of new therapies[23]. - The group maintains a robust R&D pipeline, emphasizing single-dose ophthalmic products and biologics such as growth factors and antibodies[115]. Market and Distribution - The group operates a vast distribution network with 44 regional sales offices in China, covering over 14,000 hospitals and medical institutions[16]. - The distribution network allows the company's therapeutic products to be prescribed in over 14,000 hospitals and medical institutions, as well as approximately 1,810 pharmacies across major cities, provinces, and counties in China[49]. - The company aims to increase patient accessibility in lower-tier cities in China and expand clinical indications for its commercialized products[17]. - The company is actively seeking new therapies in oncology, orthopedics, and neurology through strategic investments[115]. Corporate Governance and Compliance - The board has adhered to the corporate governance code as outlined in Appendix C1 of the Listing Rules during the review year[191]. - The board is responsible for preparing true and fair consolidated financial statements according to Hong Kong Financial Reporting Standards and the Companies Ordinance[200]. - Internal controls are required to prevent significant misstatements due to fraud or error in the financial statements[200]. - The company emphasizes compliance with various local laws and regulations, including those related to drug production and environmental standards[141]. Shareholder Information - The board has proposed a final dividend of HKD 0.06 per ordinary share for 2023, up from HKD 0.045 in 2022, with a total dividend of HKD 0.12 per share for 2024[26]. - The company has a distributable reserve of HKD 37,074,533 as of December 31, 2024, with HKD 34,027,740 proposed for the final dividend for the review year[166]. - The top five customers accounted for approximately 52.3% of the total sales, with the largest customer contributing about 27.0%[168]. - The top five suppliers represented approximately 53.1% of total purchases, with the largest supplier accounting for about 17.8%[168]. Legal and Regulatory Matters - The company is actively defending against allegations from Guangxi Wanshoutang Pharmaceutical Co., Ltd. regarding a sales agency agreement and has filed a counterclaim for outstanding payments[60]. - The Chinese government has initiated a national drug procurement program focused on volume-based purchasing, aiming to lower drug prices through competitive bidding[132]. - The implementation of this program may negatively impact the company's existing operations and commercialization strategies in China[132]. Employee and Social Responsibility - The group provides stock options and bonuses to employees based on performance and financial results, as determined by the board of directors[90]. - Employee development is a priority, with competitive compensation and training programs offered to enhance skills[144]. - The group made charitable donations totaling approximately HKD 887,000 during the review year, compared to HKD 481,000 in 2023[167]. - The company is committed to creating an environmentally friendly work environment by promoting energy conservation and recycling[133].

亿胜生物科技(01061)公布，用以治疗湿性AMD中国患者的anti-VEGF眼用注射生物药品(HLX04-O)的三 期临床研究(AURA-1)结果已达到主要研究终点。 除已达到主要研究终点的AURA-1外，HLX04-O在湿性AMD患者中开展的国际多中心三期临床研究正 于多个欧洲国家、澳大利亚、美国及中国有序开展(AURA-2)，并于2025年一月完成最后一名患者的最 后一次访视。 HLX04-O是在复宏汉霖自主研发的汉贝泰(贝伐珠单抗注射液)的基础上，根据眼科用药的需求对汉贝泰 (贝伐珠单抗注射液)的处方、规格和生产工艺进行优化，在活性成份不变的基础上，开发的新的眼科制 剂产品，拟用于湿性AMD的治疗。 AURA-1为一项多中心、随机、双盲、阳性对照的非劣效三期临床研究，旨在比较HLX04-O与雷珠单抗 玻璃体腔注射(IVT)治疗新诊断湿性AMD患者的有效性和安全性。入组的患者按照1:1的比例随机接受 HLX04-O(1.25mg)IVT或雷珠单抗(0.5mg)IVT给药，每四周一次，在患者未发生死亡、撤回知情同意、 失访或申办方终止研究的情况下，治疗持续一年。本次研究的主要研究终点为第48周最佳矫正视力 ...

Financial Performance - The company's revenue for the year ended December 31, 2024, was HKD 1,669,817, a decrease of 3.9% compared to HKD 1,736,972 in 2023[3] - Net profit for the year increased by 11.6% to HKD 307,222 from HKD 275,260 in the previous year[3] - Total comprehensive income for the year was HKD 260,658, an increase from HKD 244,925 in 2023[4] - Total external customer revenue for the year ended December 31, 2024, was HKD 1,662,297,999, a decrease from HKD 1,731,873,976 in 2023[16] - The group's revenue for the year ending December 31, 2024, was approximately HKD 1,669.8 million, a decrease of 3.9% from HKD 1,737.0 million in 2023[68] - Despite the revenue decline, the group achieved a net profit of approximately HKD 307.2 million, an increase of 11.6% from HKD 275.3 million in 2023[68] Assets and Liabilities - Total assets rose by 5.5% to HKD 2,983,045, while total liabilities decreased by 4.9% to HKD 859,325[3] - The company's total assets increased to HKD 1,246,836,875 in 2024, up from HKD 1,153,040,731 in 2023, marking an increase of approximately 8.1%[25] - The company’s total liabilities related to intangible assets increased to HKD 929,878,947 in 2024, up from HKD 854,313,383 in 2023, reflecting an increase of about 8.8%[25] - The group’s debt-to-asset ratio was 28.8% as of December 31, 2024, down from 32.0% in 2023[77] Cash Flow and Dividends - The company's cash and cash equivalents increased by 9.3% to HKD 557,167 from HKD 509,845 in 2023[3] - The company declared a total dividend of HKD 0.12 per share, a 33.3% increase from HKD 0.09 in 2023[3] - The proposed final dividend is HKD 0.06 per share for 2024, compared to HKD 0.045 per share in 2023, representing a 33.3% increase[22] - The group's cash and cash equivalents amounted to approximately HKD 557,200,000 as of December 31, 2024, compared to HKD 509,800,000 as of December 31, 2023[77] Research and Development - The company plans to continue expanding its market presence and investing in new product development[3] - Research and development costs recognized as expenses were HKD 25,009,026 in 2024, down from HKD 39,144,729 in 2023[19] - The group plans to increase R&D investment and strengthen collaborations with research institutions and universities to foster innovation[66] - The company is actively pursuing multiple R&D projects at various clinical stages, focusing on single-dose ophthalmic products and biologics[44] Product Development and Market Potential - The company received NMPA approval for preservative-free single-dose sodium hyaluronate eye drops and sodium hyaluronate (0.3%) in August and September 2024, respectively, expanding its product offerings[42] - The estimated number of moderate to severe dry eye patients in China is around 111,600,000 by 2024, indicating a significant market potential for SkQ1[47] - The total investment cost for SkQ1's clinical development and global rights amounts to approximately HKD 344,000,000, representing 11.5% of the company's total assets as of December 31, 2024[47] - The joint development agreement with Shanghai Junshi Biosciences for the anti-VEGF product has a maximum commitment investment of USD 67,000,000 (approximately HKD 520,300,000)[50] Operational Efficiency - The gross profit margin remained stable at 89.8%, while the net profit margin improved to 18.4% from 15.8%[3] - The current ratio improved to 1.81 from 1.54, indicating better short-term financial health[3] - Employee costs (excluding director remuneration) amounted to HKD 309,070,741 in 2024, compared to HKD 298,225,948 in 2023[19] - Distribution and selling expenses were approximately HKD 934.2 million, a decrease of 7.7% from HKD 1,012.0 million in 2023[70] Corporate Governance and Management - The company has adhered to the corporate governance code as per the listing rules throughout the year[90] - The audit committee has reviewed and recommended the approval of the audited consolidated financial statements for the year ending December 31, 2024[97] - The company has appointed Mr. Yan Xianlong as the CEO effective July 1, 2025, pending shareholder approval[91] - Mr. Yan Xianlong has over 10 years of experience in translational and therapeutic research prior to joining the company in 2015[92] Legal and Regulatory Matters - A court ruling in May 2024 ordered the contractor to pay approximately HKD 31.1 million as compensation for breach of contract, which is lower than the amount claimed by the company[63] - The company is actively defending against allegations from Guangxi Wanshoutang Pharmaceutical Co., Ltd. regarding exclusive sales agreements and has filed a counterclaim for outstanding payments[64]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 5.12, indicating a potential upside of 73% from the current price of HKD 2.95 [18][40][41]. Core Insights - The company experienced a temporary decline in performance due to adverse market conditions influenced by tightened regulatory policies in the healthcare sector, leading to a 9.8% decrease in revenue to HKD 812 million for the first half of 2024 [3][14]. - The company is advancing the research and development of Bevacizumab (HLX04-O), which is currently undergoing Phase III clinical trials in multiple regions including the US, EU, China, and Australia, with a new drug application expected to be submitted in 2025 [25][42]. - The potential market for Bevacizumab is significant, particularly for conditions like wet AMD and diabetic macular edema, with an estimated 15.8 million patients in China [25][42]. Financial Summary - The company reported a net profit of HKD 157 million for the first half of 2024, a decrease of 7.3% year-on-year [3][14]. - Revenue projections for 2024-2026 are estimated at HKD 16.82 billion, HKD 18.23 billion, and HKD 19.82 billion respectively, with corresponding EPS of HKD 0.47, HKD 0.50, and HKD 0.54 [12][18]. - The company’s total assets are valued at HKD 2.54 billion, with total liabilities of HKD 1.13 billion, indicating a solid financial position [8][20].

欢迎出席益生生物科技2024年度业绩发布会今天出席会议的有益生生物科技总术会主席闫明志先生 董事总经理方海舟先生Managing Director Mr. 方海舟大家好副董事总经理严贤龙先生Deputy Managing Director Mr. Malcolm Young大家好首席财务总监邱丽文女士Chief Financial Officer Mr. Agnes YaoHello, good morning以及首席科学家薛琪博士and Chief Scientific Officer Dr. Quinn Xue 益社生物科技是一间专注于研发、生产和销售基因工程药物BFGF的生物制药企业拥有包括背复书、背复记、背复心在内的六种基因工程药物在中国上市销售此外,公司还拥有包含一系列不含防腐剂干剂量的眼液和视力顺软灵石落合碘胶囊等多元化产品组合 主席我们我们马上开始了可以打开摄像头你有回音回音很厉害对刚才Jeffrey关掉了对现在OK吗可以 好的我也再次提醒一下大家整个业绩会过程中除了播放视频的时候之外其他时候我们的视频都是打开的所以观众都是可以看到我们的提醒一下那么我们现在就开始了尊敬的各位投资者分析师大家上午 ...

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 811,630,000, a decrease of 9.8% compared to HKD 899,359,000 for the same period in 2023[1] - Gross profit for the period was HKD 724,612,000, down from HKD 810,462,000, reflecting a decline of 10.6%[1] - The company reported a net profit of HKD 157,440,000, compared to HKD 169,811,000 in the previous year, representing a decrease of 7.3%[1] - Basic earnings per share for the period were HKD 0.2774, down from HKD 0.2972, a decrease of 6.6%[1] - The company’s total comprehensive income for the period was HKD 94,632,000, down from HKD 169,811,000 in the previous year, representing a decline of about 44.3%[3] - Profit for the period decreased by 7.3% to approximately HKD 157.4 million, down from approximately HKD 169.8 million in the previous year[62] Assets and Liabilities - Total assets as of June 30, 2024, were HKD 2,965,806,000, up from HKD 2,827,558,000 at the end of 2023, indicating a growth of 4.9%[2] - Current assets increased to HKD 1,387,634,000 from HKD 1,245,277,000, reflecting an increase of 11.4%[2] - The company's total liabilities rose to HKD 950,326,000 from HKD 903,781,000, an increase of 5.2%[2] - The net asset value increased to HKD 2,015,480,000 from HKD 1,923,777,000, showing a growth of 4.8%[2] Cash Flow and Financing - Cash generated from operating activities before tax was HKD 197,380,000, down from HKD 204,855,000 in the previous year, indicating a decline of about 3.5%[4] - The company experienced a significant increase in cash flow from operating activities, amounting to HKD 161,833,000, compared to HKD 140,978,000 in the prior year, reflecting an increase of approximately 14.8%[4] - The company’s cash flow from financing activities showed a net outflow of HKD 30,169,000, compared to an inflow of HKD 14,028,000 in the previous year, indicating a shift in financing strategy[4] - The net cash flow from financing activities for the six months ended June 30, 2024, was HKD 96,789,000, with cash and cash equivalents increasing to HKD 598,414,000[5] Revenue Segmentation - For the six months ended June 30, 2024, the total revenue from external customers was HKD 811,630,000, with ophthalmology contributing HKD 375,560,000 and surgery contributing HKD 436,070,000[10] - Revenue from the ophthalmology segment contributed approximately HKD 375.5 million, a decrease of 1.6%, while the surgical segment recorded revenue of approximately HKD 436.1 million, a decrease of 15.8%[62] - The flagship biopharmaceutical products, Beifu Shu® and Beifu Ji®, accounted for approximately 86.4% of total revenue, with Beifu Shu® contributing 35.4% and Beifu Ji® contributing 51.0%[62] Research and Development - Research and development costs recognized as expenses were HKD 12,479,000 in 2024, down from HKD 20,250,000 in 2023, showing a decrease of 38.5%[20] - The company has initiated a five-year R&D plan starting from 2021 to enhance its capabilities in the ophthalmology field, focusing on growth factors, antibodies, and drug formulation technologies[58] - As of June 30, 2024, the company has a pipeline of 5 commercially available preservative-free single-dose eye drops, with plans to commercialize additional products in the next 2 to 5 years[58] Market Expansion and Strategy - The company plans to continue its market expansion and product development strategies, although specific figures were not disclosed in the current report[3] - The company has a strong focus on expanding its market presence in lower-tier cities in China and Southeast Asia[57] - The group is strategically expanding into new therapeutic areas such as oncology, orthopedics, and neurology through strategic investments[52] Shareholder Information - The company declared an interim dividend of HKD 0.06 per share for the six months ended June 30, 2024, up from HKD 0.045 per share in 2023, an increase of 33.3%[22] - The total number of shares repurchased was 35,000, with a maximum price of HKD 2.45 per share during January 2024[82] - As of June 30, 2024, the company’s major shareholder, Yan Mingchi, holds 153,945,667 shares, representing approximately 27.13% of the issued share capital[78] Legal and Compliance - The company is involved in a legal dispute with Guangxi Wanshoutang Pharmaceutical Co., which it firmly denies, and is seeking professional legal advice[61] - The company has complied with the corporate governance code as per the listing rules throughout the review period[82] - All directors confirmed compliance with the securities trading regulations during the six-month period ending June 30, 2024[86]

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 811,630,000, a decrease of 9.8% compared to HKD 899,359,000 for the same period in 2023[2] - Profit for the period was HKD 157,440,000, down 7.3% from HKD 169,811,000 in the previous year[2] - Gross profit margin decreased to 89.3% from 90.1% year-on-year[2] - Net profit margin was 19.4%, compared to 18.9% in the same period last year[2] - The total comprehensive income for the period was HKD 94,632,000, down from HKD 169,811,000, indicating a decline of 44.3%[9] - The profit before tax for the six months ended June 30, 2024, was HKD 197,380,000, slightly down from HKD 204,855,000 in the previous year, a decrease of 3.6%[10] - The company reported a net profit attributable to shareholders of HKD 157,440,000 for the six months ended June 30, 2024, down from HKD 169,811,000 in 2023, reflecting a decrease of approximately 7%[28] - Basic earnings per share for the six months ended June 30, 2024, was HKD 0.27, compared to HKD 0.30 for the same period in 2023, indicating a decline of about 10%[28] Assets and Liabilities - Total assets increased by 4.9% to HKD 2,965,806,000 from HKD 2,827,558,000[3] - Total liabilities rose by 5.2% to HKD 950,326,000 from HKD 903,781,000[3] - Cash and cash equivalents increased by 17.4% to HKD 598,414,000 from HKD 509,845,000[3] - The current ratio improved to 1.68 from 1.54[4] - As of June 30, 2024, the net current assets increased to HKD 563,430,000 from HKD 434,533,000 as of December 31, 2023, representing a growth of 29.6%[8] - Total assets less current liabilities rose to HKD 2,141,602,000, up from HKD 2,016,814,000, indicating an increase of 6.2%[8] - The total liabilities increased to HKD 950,326,000 from HKD 903,781,000, reflecting a rise of 5.1%[8] - The net asset value reached HKD 2,015,480,000, compared to HKD 1,923,777,000, marking an increase of 4.8%[8] Cash Flow - Operating cash flow for the six months ended June 30, 2024, was HKD 161,833,000, compared to HKD 140,978,000 for the same period in 2023, showing a growth of 14.8%[10] - The net cash used in investing activities was HKD 40.82 million, a significant improvement from HKD 106.80 million in the same period last year[11] - The company reported a net cash inflow from financing activities of HKD 5.95 million, contrasting with a net outflow of HKD 71.62 million in the prior year[11] - The cash flow from operating activities was not detailed, but the overall cash position improved significantly due to better management of cash inflows and outflows[11] Dividends - The company declared an interim dividend of HKD 0.06 per share, up from HKD 0.045 per share in the previous year[2] - The company paid dividends amounting to HKD 25,539,000 during the period[9] - The board declared an interim dividend of HKD 0.06 per share for the six months ending June 30, 2024, compared to HKD 0.045 for the same period in 2023[101] Research and Development - Research and development costs recognized as expenses were HKD 12,479,000 in 2024, down from HKD 20,250,000 in 2023, reflecting a reduction of about 38%[24] - The company has a pipeline of 16 R&D projects, with 4 ophthalmology projects currently in clinical stages, which are seen as mid-term growth drivers[67] - The company has initiated a five-year R&D plan to enhance its capabilities in the ophthalmology sector, focusing on therapies that meet unmet clinical needs[65] Market and Product Development - The company continues to focus on the development and sales of biopharmaceuticals, with ongoing investments in new product development and market expansion strategies[12] - The company has established strategic collaborations with Antikor Biopharma Limited and Fuhong Hanlin to advance its biopharmaceutical development in oncology and ophthalmology[66] - The group has received NMPA approval for preservative-free single-dose eye drops, expanding its product portfolio[58] - The flagship biopharmaceutical products, Beifu Shu® series and Beifu Ji® series, contributed approximately 86.4% of total revenue, with Beifu Shu® series at 35.4% and Beifu Ji® series at 51.0%[73] Employee and Management - The group had a total of 1,459 full-time employees as of June 30, 2024, a decrease from 1,481 employees as of December 31, 2023[87] - Total employee compensation for the review period was approximately HKD 159.4 million, compared to approximately HKD 173 million in the previous period[87] - The remuneration paid to key management personnel for the six months ended June 30, 2024, was HKD 3,644,000, compared to HKD 3,675,000 for the same period in 2023[55] Corporate Governance - The company has complied with the corporate governance code as per the listing rules throughout the review period[99] - The audit committee reviewed the accounting principles and practices adopted by the group, discussing internal controls and financial reporting matters[100] - All directors confirmed compliance with the standards set forth in the code regarding securities transactions during the review period[103]

欢迎各位投资者参加华安医药联合录影中举办的夏季现场策略会本场会议主持人是华安医药唐国超唐老师 本场是上市公司易胜生物科技的交流很荣幸能够邀请到公司的领导董事总经理方海东方总和高级II经理陈月峰陈总与我们一起交流我们今天的交流呢分为公司介绍和问答环节两个部分首先呢有请公司领导陈总用20到30分钟的时间对公司的一个经营情况最新进展的做一个讲解就请陈总 谢谢李总,然后谢谢今天出空参加我们公司专场的投资者们,我是医生生物的IR陈月峰,下面先由我对公司进行一个介绍。 医生生物是一家专注于研发、生产和销售基因工程药物RBBFGF的生物制药企业已有包括贝福输、贝福计、贝福鑫在内的6种基因工程药物在中国上市销售 此外,公司还拥有一系列不含防腐剂的单剂量低盐液和贝弗氏立胜软磷脂洛克碘胶囊等产品主要应用于眼科及皮肤科、处方药领域的创伤修复及疾病治疗在中国已经成功覆盖逾12500家医院及1800家药店 公司依托自身在生产因子和抗体领域的研发平台拥有多个临床阶段的项目涵盖多项领域和适应症总而言之益胜是生产因子的领先者因为我们拥有全球首款的BFGF产品BFGF冻干粉 全球首款BFGF沿用聚集被服输的眼液以及在此基础上开发了一系列的全球 ...

欢迎各位投资者参加华安医药联合录影中举办的夏季现场策略会本场会议主持人是华安医药谈博超谈老师 本场是上市公司易胜生物科技的交流很荣幸能够邀请到公司的领导董事总经理方海东方总和高级II经理陈月峰陈总与我们一起交流我们今天的交流分为公司介绍和问答环节两个部分首先有请公司领导陈总用20到30分钟的时间对公司的一个经营情况最新进展的做一个讲解有请陈总 谢谢李总,然后谢谢今天出空参加我们公司专场的投资者们我是一生生物的IR陈月峰,下面先由我对公司进行一个介绍 医生生物是一家专注于研发、生产和销售基因工程药物RBBFGF的生物制药企业已有包括贝福输、贝福计、贝福鑫在内的6种基因工程药物在中国上市销售 此外,公司还拥有一系列不含防腐剂的单剂量滴眼液和贝弗氏立胜软磷脂洛合碘胶囊等产品主要应用于眼科及皮肤科、处方药领域的创伤修复及疾病治疗在中国已经成功覆盖逾12500家医院及1800家药店 公司依托自身在生产因子和抗体领域的研发平台拥有多个临床阶段的项目涵盖多项领域和适应症总而言之益胜是生产因子的领先者因为我们拥有全球首款的BFGF产品BFGF冻干粉 全球首款BFGF沿用致敬被服输的眼液以及在此基础上开发了一系列的全球首款的产 ...